Huang Xuemei, Han Dongshan, Wei Yanfei, Lin Bingchun, Zeng Dingyuan, Zhang Yu, Wei Ba, Huang Zhifeng, Chen Xueyu, Yang Chuanzhong
Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, The First School of Clinical Medicine, Southern Medical University, Shenzhen, China.
Department of Neonatology, Liuzhou Maternity and Child Healthcare Hospital, Affiliated Maternity Hospital and Affiliated Children's Hospital of Guangxi University of Science and Technology, Liuzhou, China.
Front Pediatr. 2022 Jul 26;10:919879. doi: 10.3389/fped.2022.919879. eCollection 2022.
Ibuprofen is one of the most common non-steroidal anti-inflammatory drugs used to close patent ductus arteriosus (PDA) in preterm infants. PDA is associated with bronchopulmonary dysplasia (BPD), while PDA closure by ibuprofen did not reduce the incidence of BPD or death. Previous studies have indicated an anti-angiogenesis effect of ibuprofen. This study investigated the change of angiogenic factors after ibuprofen treatment in preterm infants.
Preterm infants with hemodynamically significant PDA (hsPDA) were included. After confirmed hsPDA by color doppler ultrasonography within 1 week after birth, infants received oral ibuprofen for three continuous days. Paired plasma before and after the ibuprofen treatment was collected and measured by ELISA to determine the concentrations of platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor A (VEGF-A), and hypoxia-inducible factor-2α (HIF-2α).
17 paired plasma from infants with hsPDA were collected. The concentration of PDGF-BB and VEGF-A significantly decreased after ibuprofen treatment (1,908 vs. 442 pg/mL for PDGF-BB, 379 vs. 174 pg/mL for VEGF-A). HIF-2α level showed a tendency to decrease after ibuprofen treatment, although the reduction was not statistically significant ( = 0.077).
This study demonstrated decreased vascular growth factors after ibuprofen exposure in hsPDA infants.
布洛芬是用于闭合早产儿动脉导管未闭（PDA）的最常见非甾体抗炎药之一。PDA与支气管肺发育不良（BPD）相关，而布洛芬闭合PDA并未降低BPD或死亡的发生率。先前的研究表明布洛芬具有抗血管生成作用。本研究调查了布洛芬治疗后早产儿血管生成因子的变化。
纳入有血流动力学意义的PDA（hsPDA）的早产儿。出生后1周内通过彩色多普勒超声确诊为hsPDA后，婴儿连续3天口服布洛芬。收集布洛芬治疗前后的配对血浆，通过酶联免疫吸附测定法（ELISA）测定血小板衍生生长因子-BB（PDGF-BB）、血管内皮生长因子A（VEGF-A）和缺氧诱导因子-2α（HIF-2α）的浓度。
收集了17例hsPDA婴儿的配对血浆。布洛芬治疗后，PDGF-BB和VEGF-A的浓度显著降低（PDGF-BB：1908 vs. 442 pg/mL，VEGF-A：379 vs. 174 pg/mL）。布洛芬治疗后HIF-2α水平呈下降趋势，尽管下降无统计学意义（P = 0.077）。
本研究表明，hsPDA婴儿暴露于布洛芬后血管生长因子减少。
